Enanta Pharmaceuticals Announces the Appointment of Timothy D. Ocain, Ph.D. as Senior Vice President, New Product Strategy & ...
February 03 2014 - 4:10PM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced the
appointment of Timothy D. Ocain, Ph.D. as Senior Vice President,
New Product Strategy and Development. Dr. Ocain has over 25 years’
experience working in the pharmaceutical and biotechnology
environment with experience in medicinal chemistry, pharmacology,
biochemistry, program management and preclinical and early
development across multiple therapeutic areas. He is co-author on
over 30 publications and co-inventor on 17 patents.
“As Enanta begins to advance its internal candidates and seeks
new development areas, Tim’s broad experience in drug discovery and
business development will be an invaluable resource to the
company,” stated Jay R. Luly, Ph.D. President and Chief Executive
Officer.
Dr. Ocain has held senior management and executive positions
across a wide range of small, mid and large cap biotechnology and
pharmaceutical companies. Since 2010, Dr. Ocain has been an
independent biotechnology consultant providing consulting services
to a variety of companies. From 2006-2009, he was a member of the
executive team as the Senior Vice President, Research and
Development at Seaside Therapeutics, a company focused on
neurodevelopmental disorders. Previously, he worked at Millennium
Pharmaceuticals from 1998-2006 and held positions of increasing
responsibility in drug discovery, program management and mostly
recently held the position of Vice President, Inflammation
Discovery. From 1993-1998 he worked at Procept, Inc, where he held
senior level drug discovery positions, with additional
responsibility for business development activities. Prior to
Procept, he served in the medicinal chemistry department at
Wyeth-Ayerst Research from 1986-1993.
Dr. Ocain received his B.S. in Biological Sciences from the
University of Wisconsin-Eau Claire and his Ph.D. in Pharmaceutical
Chemistry from the University of Wisconsin-Madison, and completed
his post-Doctoral Fellowship in Chemistry at the University of
Minnesota.
About Enanta
Enanta Pharmaceuticals is a research and development-focused
biotechnology company that uses its robust chemistry-driven
approach and drug discovery capabilities to create small molecule
drugs in the infectious disease field. Enanta is discovering, and
in some cases developing, novel inhibitors designed for use against
the hepatitis C virus (HCV). These inhibitors include members of
the direct acting antiviral (DAA) inhibitor classes – protease
(partnered with AbbVie), NS5A (partnered with Novartis) and
nucleotide polymerase – as well as a host-targeted antiviral (HTA)
inhibitor class targeted against cyclophilin. Additionally, Enanta
has created a new class of antibiotics, called Bicyclolides, for
the treatment of multi-drug resistant bacteria, with a focus on
developing an intravenous and oral treatment for hospital and
community MRSA (methicillin-resistant Staphylococcus aureus)
infections.
InvestorEnanta Pharmaceuticals, Inc.Carol Miceli,
617-607-0710cmiceli@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jul 2023 to Jul 2024